Acadia's Rett Syndrome Drug Hits European Regulatory Snag, Company to Appeal Decision
Acadia Pharmaceuticals faces a setback as European regulators issue a negative opinion on its Rett syndrome therapy trofinetide, casting uncertainty over its EU approval pathway and highlighting the challenges of bringing rare disease treatments to new markets.